— Medical device maker Abiomed, Inc. (NASDAQ: ABMD) reported net income of $69.2 million or $1.51 per share for the third quarter of 2020, vs. $1.09 per share expected.
— Revenue increased 10% annually to $221.6 million during the three-month period, vs. $226.99 million expected
— US revenue rose 8% to $185.6 million, while overseas revenue moved up 29% to $36 million
— Third-quarter gross margin was 82%, down from 83% reported a year earlier
— Announced initiation of the ST-Elevation Myocardial Infarction Door-to-Unloading Pivotal Randomized Controlled Trial during the quarter
— Expects full-year 2020 revenue to be in the range of $846 million to $877 million, up 10% to 14% respectively
— Confirms full-year 2020 unadjusted operating margin guidance in the range of 28% to 30%
Most Popular
MRK Earnings: Merck Q1 2024 profit jumps on 9% revenue growth
Pharmaceutical company Merck & Co. Inc. (NYSE: MRK) reported a sharp increase in adjusted earnings for the first quarter of 2024, aided by an increase in revenues. First-quarter worldwide sales
Infographic: A snapshot of Caterpillar’s (CAT) Q1 2024 financial results
Caterpillar Inc. (NYSE: CAT), a leading manufacturer of construction and mining equipment, on Thursday reported first-quarter 2024 financial results. Sales and revenues for the first quarter of 2024 were $15.8
AAL Earnings: Key quarterly highlights from American Airlines’ Q1 2024 financial results
American Airlines Group Inc. (NASDAQ: AAL) reported its first quarter 2024 earnings results today. Total operating revenues increased 3.1% year-over-year to $12.5 billion. Net loss amounted to $312 million, or $0.48
